Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome: AControlled Trial

Berry-Kravis, Elizabeth, Krause, Sue Ellen, Block, Sandra S., Guter, Steve, Wuu, Joanne, Leurgans, Sue, Decle, Penelope, Potanos, Kristina +9 more·2006·Journal of Child and Adolescent Psychopharmacology
DOI 10.1089/cap.2006.16.525

Cited by (155)

Items 101–155 of 155

  1. Evaluating Social Interactions Using the Autism Screening Instrument for Education Planning-3rd Edition (ASIEP-3): Interaction Assessment in Children and Adults with Fragile X Syndrome
    Lisa Cordeiro, Marcia L. Braden, Elizabeth Coan, Nanastasia Welnick, Tanea Tanda, Nicole R. Tartaglia · 2020 · Brain Sciences
  2. Adaptive Skills in FXS: A Review of the Literature and Evaluation of the PEDI-Computer Adaptive Test (PEDI-CAT) to Measure Adaptive Skills
    Lisa Cordeiro, Adrienne N. Villagomez, Deanna M. Swain, Sophia Deklotz, Nicole R. Tartaglia · 2020 · Brain Sciences
  3. A ‘learning platform’ approach to outcome measurement in fragile X syndrome: a preliminary psychometric study
    Scott S. Hall, J. L. Hammond, Melissa Hirt, Allan L. Reiss · 2012 · Journal of Intellectual Disability Research
  4. Utility of the Hebb–Williams Maze Paradigm for Translational Research in Fragile X Syndrome: A Direct Comparison of Mice and Humans
    Isabelle Boutet, Charles A. Collin, Lindsey S. MacLeod, Claude Messier, Matthew R. Holahan, Elizabeth Berry‐Kravis, Reno Gandhi, Cary S. Kogan · 2018 · Frontiers in Molecular Neuroscience
  5. Reliability of resting-state electrophysiology in fragile X syndrome
    Rui Liu, Ernest V. Pedapati, Lauren Schmitt, Rebecca C. Shaffer, Elizabeth G. Smith, Kelli C. Dominick, Lisa A. DeStefano, Grace C. Westerkamp, Paul S. Horn, John A. Sweeney et al. · 2023 · Biomarkers in Neuropsychiatry
  6. Long-term follow-up of telehealth-enabled behavioral treatment for challenging behaviors in boys with fragile X syndrome
    Scott S. Hall, Arlette Bujanda Rodriguez, Booil Jo, Joy S. Pollard · 2022 · Journal of Neurodevelopmental Disorders
  7. Vocabulary comprehension in adults with fragile X syndrome (FXS)
    Anne Hoffmann, Sue Ellen Krause, Joanne Wuu, Sue L. Leurgans, Stephen J. Guter, Sandra S. Block, Jeff Salt, Edwin H. Cook, Dominick M. Maino, Elizabeth Berry‐Kravis · 2019 · Journal of Neurodevelopmental Disorders
  8. Preclinical Pharmacology of the Low-Impact Ampakine CX717
    Daniel P. Radin, Sheng Zhong, Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin, ARNOLD S. LIPPA · 2024 · Future Pharmacology
  9. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today
    Daniel P. Radin, ARNOLD S. LIPPA, Sabhya Denise Rana, David Dwight Fuller, Jodi L. Smith, Rok Cerne, Jeffrey M. Witkin · 2025 · Pharmacology Biochemistry and Behavior
  10. Neurobehavioral features and targeted treatments in fragile X syndrome: Current insights and future directions
    Dejan B. Budimirovic, Phan Q. Duy · 2015 · Engrami
  11. Safety, Tolerability, and Pharmacokinetic Profile of the Low‐Impact Ampakine CX1739 in Young Healthy Volunteers
    Daniel P. Radin, Rok Cerne, Jeffrey M. Witkin, ARNOLD S. LIPPA · 2024 · Clinical Pharmacology in Drug Development
  12. Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome
    Joan A. O’Keefe, Alejandro A. Espinoza Orías, Hassan Khan, Deborah A. Hall, Elizabeth Berry‐Kravis, Markus A. Wimmer · 2013 · Gait & Posture
  13. Genetic Approaches to Understanding Psychiatric Disease
    Jacob J. Michaelson · 2017 · Neurotherapeutics
  14. MONOGENIC DISORDERS: AN OVERVIEW.
    Usman Babar · 2017 · International Journal of Advanced Research
  15. NIH Toolbox Cognition Battery Feasibility in Individuals With Williams Syndrome
    Condy, Emma E., Becker, Lindsey, Farmer, Cristan, Kaat, Aaron J., Chlebowski, Colby, Kozel, Beth A., Thurm, Audrey · 2022 · American Journal on Intellectual and Developmental Disabilities
  16. Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763
    Daniel P. Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jeffrey M. Witkin, ARNOLD S. LIPPA · 2024 · Future Medicinal Chemistry
  17. Molecular medicine of fragile X syndrome: based on known molecular mechanisms
    Shi-Yu Luo, Lingqian Wu, Ranhui Duan · 2015 · World Journal of Pediatrics
  18. Modulating AMPA Receptors for the Treatment of CNS Disorders
    Tristan D. Reuillon, Simon E. Ward, Paul Beswick · 2017 · Elsevier eBooks
  19. Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence
    Lance Vincent Watkins, Seungyoun Moon, Lisa Burrows, Samuel Joseph Tromans, Julian Barwell, Rohit Shankar · 2024 · Expert Opinion on Pharmacotherapy
  20. Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome
    Kaizad R. Munshi, Katherine G. Pawlowski, Joseph Gonzalez–Heydrich, Jonathan D. Picker · 2017 · Journal of Child and Adolescent Psychopharmacology
  21. Aberrant Behavior Checklist
    Cristan Farmer, Michael G. Aman · 2020 · Springer eBooks
  22. Overview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome
    Andrew Ligsay, Randi Jenssen Hagerman, Elizabeth Berry‐Kravis · 2017 · Elsevier eBooks
  23. Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
    Michael Telias · 2019 · Current Pharmaceutical Design
  24. Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia
    Daniel P. Radin, Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin, ARNOLD S. LIPPA · 2025 · Journal of Psychiatric Research
  25. Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
    Sebastian Scharf, F. Gasparini, W. Spooren, L. Lindemann · 2017 · Elsevier eBooks
  26. Psychiatric Disorders in Individuals with Intellectual Disabilities
    Mendy Minjarez, Jennifer M. Phillips, Carl Feinstein, Antonio Y. Hardan · 2011 · WORLD SCIENTIFIC eBooks
  27. Fragile X Syndrome
    Anne Hoffmann, Elizabeth Berry‐Kravis · 2016 · Elsevier eBooks
  28. From bedside to bench and back: Translating ASD models
    Hayley P. Drozd, Sotirios F. Karathanasis, Andrei I. Molosh, Jodi L. Lukkes, D. Wade Clapp, Anantha Shekhar · 2018 · Progress in brain research
  29. Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds
    Meredith A. Nelson, Lauren Schmitt, Paul S. Horn, Elizabeth Berry‐Kravis, David R. Hessl, Rebecca C. Shaffer, Randall Carpenter, Dejan B. Budimirovic, Paul Wang, Debra L. Reisinger et al. · 2024 · Journal of Autism and Developmental Disorders
  30. Acute Administration of Ampakine CX1739 after Cervical Spinal Cord Injury
    Anna F. Fusco, Sabhya Denise Rana, Maya M. Macintyre, I. Hernando González, Roberto A. Ribas, Ramon C. Sun, David Dwight Fuller · 2025 · Journal of Neurotrauma
  31. Clinical Trial Designs for Rare Disorders
    Adam V. Steenbergen, Manpreet Kaur, Keneizha Rubanarayana, François V. Bolduc · 2026 · Neurology Genetics
  32. Motor stereotypies in fragile X syndrome
    Victor Kaytser, Elizabeth Berry‐Kravis, Bichun Ouyang, Emily R. Doll, Deborah Hall · 2015 · Journal of Pediatric Neurology
  33. Postępy w leczeniu zespołu łamliwego chromosomu X
    Małgorzata Lisik, Aleksander L. Sieroń · 2010 · Neurologia i Neurochirurgia Polska
  34. Reflections on Clinical Trials in Fragile X Syndrome
    Aia Elise Jønch, Sébastien Jacquemont · 2017 · Elsevier eBooks
  35. Medication Management of Fragile X Syndrome
    Craig A. Erickson, Logan K. Wink, Tori L. Schaefer, Rebecca C. Shaffer · 2013 · Springer eBooks
  36. From genes to brain to behavior: the case of fragile X syndrome
    Susan Michelle Rivera, Allan L. Reiss · 2009 · Cambridge University Press eBooks
  37. The quest for treatment of cognitive impairment: AMPA and mGlu5 receptor modulators
    Miao‐Kun Sun · 2008 · Expert Opinion on Therapeutic Patents
  38. Phase II and III drugs for the treatment of fragile X syndrome
    Laura C. Politte, Christopher J. McDougle · 2012 · Expert Opinion on Orphan Drugs
  39. Fragile X Syndrome and X-linked Intellectual Disability
    Kathryn B. Garber, Stephen T. Warren, Jeannie Visootsak · 2013 · Elsevier eBooks
  40. Drug Treatments for Pervasive Developmental Disorders: Expanding the Evidence Base
    James T. McCracken · 2006 · Journal of Child and Adolescent Psychopharmacology
  41. Visual Spatial Learning and Memory in Fragile X Syndrome and fmr1 Knockout Mice
    Lindsey S. MacLeod · 2013 · uO Research (University of Ottawa)
  42. Congenital causes
    Jessica A. Hellings, Merlin G. Butler, J. A. Grant · 2001 · Cambridge University Press eBooks
  43. Lujan Fryns Syndrome - A Case Report
    Amit Soni, Ajita Meenawat, Khyati Soni, Vivek Srivastava, Brampton Ontario, Chandra Dental · 2014
  44. Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
    Christoph Kamm · 2013 · Clinical Investigation
  45. Therapiekonzepte bei genetischen Syndromen mit mentaler Retardierung
    Heymut Omran, Jutta Kunde-Trommer, Rainer Blank · 2014 · Elsevier eBooks
  46. Fragile X syndrome, an X-linked dominant disorder with reduced penetrance, is associated with intellectual
    Kathryn B. Garber, Jeannie Visootsak, Stephen T. Warren · 2008
  47. Dysregulated ERK signal pathway and immune profiles in Fragile X Syndrome
    Ning Weng · 2012 · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
  48. Genetische Erkrankungen
    2009 · Elsevier eBooks
  49. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study
    Isha R. Jalnapurkar, Jean A. Frazier, Mark Roth, David Cochran, Ann Foley, Taylor Merk, Lauren Venuti, Lucienne V. Ronco, Shane R. Raines, Diego Cadavid · 2022 · Journal of Neurodevelopmental Disorders
  50. Measuring Effectiveness of Treatments in Rare Disorders, Evidence from Clinical Trials in Fragile X Syndrome
    Adam V. Steenbergen, Amrita Minhas, Tony R. Lin, Manpreet Kaur, François V. Bolduc · 2023 · Research Square
  51. Autism spectrum disorder and the role of nuclear hormone receptors: insights and therapeutic implications
    Shivakanth Chintalapally, Kalpana Rajanala, Arun K. Upadhyay · 2025 · Frontiers in Neuroscience
  52. Potential pharmacological treatment of fragile X syndrome during adulthood
    Zhaohui Xu, Ming Zhao · 2009 · Neuroscience Bulletin
  53. Additional file 1 of The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study
    Isha R. Jalnapurkar, Jean A. Frazier, Roth, Mark, David Cochran, Foley, Ann, Taylor Merk, Lauren Venuti, Lucienne V. Ronco, Shane R. Raines, Diego Cadavid · 2023 · Figshare
  54. Additional file 1 of Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
    Leonard Abbeduto, Elizabeth Berry‐Kravis, Audra M. Sterling, Sherman, Stephanie, Jamie Ogline Edgin, Andrea S. McDuffie, Hoffmann, Anne, Hamilton, Debra, Nelson, Michael, Jeannie R. Aschkenasy et al. · 2020 · Figshare
  55. Therapeutic potential of positive allosteric modulators of AMPA receptors in brain disorders
    Alessio Spinola, Maria Italia, Fabrizio Gardoni · 2026 · Biomedicine & Pharmacotherapy